J&J’s Incivo Shows “Hints” Of Added Benefit, Says Germany’s IQWiG
This article was originally published in The Pink Sheet Daily
Executive Summary
IQWiG concludes that J&J/Vertex’s new Hep C drug Incivo might be helpful in certain patient groups, but the German HTA body questions the validity of a widely-used surrogate efficacy measure.
You may also be interested in...
Intermune’s Esbriet Flops In Front Of IQWiG
Germany’s IQWiG remains unconvinced about the added value offered by Intermune’s Esbriet, a decision that adds to industry concerns on assessment methodology
AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward
Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.
Pandemic Spotlights Tensions Between Profit And Philanthropy
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: